Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.
What are tumour agnostic cancer treatments and which biomarkers do they target? Join Prof. David Hong (Medical Oncologist at MD Anderson Cancer Center, Houston,...
Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debra Montague,...
This podcast episode provides an introduction to molecular testing in the diagnosis and treatment of cancer. Prof. David Hong from MD Anderson Cancer Center,...